Enhancing Antigen Presentation and Inducing Antigen-Specific Immune Tolerance with Amphiphilic Peptides

Area of Science:

• Immunology
• Endocrinology
• Biotechnology

Background:

• Ag-specific immunotherapy aims to restore immune tolerance for autoimmune disorders like type 1 diabetes (T1D) without global immune suppression.
• Previous autoantigen vaccination trials in human T1D have largely failed, highlighting challenges in inducing peripheral tolerance.
• Efficient autoantigen presentation by antigen-presenting cells (APCs) is crucial for successful vaccination-based tolerance induction.

Purpose of the Study:

• To investigate if lipophilic modification of CD4+ epitopes enhances peptide antigen presentation by APCs.
• To evaluate the efficacy of amphiphilic lipo-peptides in inducing Ag-specific immune tolerance and controlling T1D in a mouse model.
• To determine if lipo-peptide treatment can delay or reverse autoimmune diabetes progression.

Main Methods:

• Designed amphiphilic lipo-peptides by modifying CD4+ epitopes with a lipophilic N-terminal group.
• Investigated APC targeting and albumin binding of lipo-peptides in lymph nodes.
• Assessed peptide anchoring to APC membranes for bivalent cell-surface antigen presentation.
• Administered lipo-peptides or soluble peptides to NOD mice and monitored T cell activation, cytokine production, regulatory T cells, and diabetes incidence.

Main Results:

• Lipophilic modification dramatically improved peptide antigen presentation by APCs.
• Amphiphilic lipo-peptides efficiently targeted APCs in lymph nodes and enhanced antigen presentation potency and duration.
• Immunization with an insulin B chain 9-23 lipo-peptide suppressed T cell activation, increased inhibitory cytokines, induced regulatory T cells, and delayed T1D onset in NOD mice.
• Treatment with a lipophilic β-cell peptide mixture delayed progression to end-stage diabetes in acutely diabetic NOD mice, unlike soluble peptides.

Conclusions:

• Amphiphilic lipo-peptide modification is an effective strategy to enhance antigen presentation for peptide-based immune regulation.
• This approach holds promise for developing novel immunotherapies for autoimmune diseases like type 1 diabetes.
• Lipophilic modification enables robust Ag-specific immune tolerance by improving APC presentation and function.